[ Archive Home ]
Tianjin Zhong Xin Pharm| [ Archive Home ] |
| Tianjin Zhong Xin Pharm |
| Pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 of 130 |
(Post 1 of 6500) 07/12/1999.23:51:00 |
| Author : |
Notice TJ hav fallen twice below its 50 days ma, furthermore, 10days ma also fallen below 20 days ma (mid and short term outlook rather -ve.) Currently it could be rather oversold, but a return on the upside (if any) would very limited below the 20 days ma (or to be more pessimistic, even 10 days ma will also be hard to surpass in short-term). (Do note that all assumption were base on closing, intra-day high/low were neglected like I've mentioned b4 long ago) Rdgs |
| (Post 2 of 6500) 11/15/1999.20:05:00 |
| Author : |
lion this stock came back to life this afternoon any update |
| (Post 3 of 6500) 11/18/1999.10:23:00 |
| Author : |
Could anyone tell me what is with this counter? Bot it two days ago at 55cents 10 lots and saw it fall to 51.5 cents to day.. Is it a safe share to keep? Thanks |
| (Post 4 of 6500) 12/23/1999.14:55:00 |
| Author : |
TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED The associated company of Tianjin Zhong Xin Pharmaceutical Group Co.,Ltd-Tianjin Bieffe Medital Pharmaceutical Co.,Ltd is a joint venture company which Italian Bieffe Medital S.P.A has a 70% interest in Tianjin Bieffe, with Tianjin Zhong Xin holding the remaining 30%. Because the Italian Bieffe Medital S.P.A has been purchased by Baxter Healthcare Co.,Ltd, so Tianjin Bieffe Medital Pharmaceutical Co.,Ltd resolve to change its name to Baxter Healthcare(Tianjin) Co.,Ltd did by the Board of Directors' written resolution of the associated company and the approval of the administration committee of Tianjin New Technological Property Area, Document code-No-43-1999 for Jin Yuan Qu foreign enterprises. The associated company now known by its new name with effect from 8th Nov 1999. Submitted by MO HAO, Secretary to the Board on 23th Dec 1999 to the SES |
| (Post 5 of 6500) 01/30/2000.16:37:00 |
| Author : |
TIanjinzx - Symmetric Triangle observed  - Note that there is a considerable Gap Down between US$0.46 ~ US$0.485 (RED circle) Brkout (either upside/downside) could be imminent. |
| (Post 6 of 6500) 02/16/2000.00:37:00 |
| Author : |
Keep a look out on any increase in Price Volatility. Brkout could be imminent (thou' yet to identify up/dn) Rdgs |
| (Post 7 of 6500) 02/19/2000.01:29:00 |
| Author : |
Tianjin Zhong Xin to seek CSRC approval for China listing Tianjin Zhong Xin Pharmaceutical Group Corp Ltd said it intends to submit an application to the China Securities Regulatory Commission for a proposed IPO on one of the stock exchanges in China. The A-share offer is subject to approval by the CSRC and the company's shareholders. In a statement, the company said it has appointed Tianjin Securities Co Ltd and China Eagle Securities Co Ltd as the lead and deputy lead underwriters respectively. Under its proposal, the company plans to offer up to 45.8 mln domestic investment shares, which comprise about 12.2 pct of the company's enlarged share capital on a stock exchange in China. The offer price of the A shares will be determined later at a date closer to the share offer. However, based on an internal assessment, the estimated range of the offer price is 5.50-8.50 yuan per share. The company said the move to list its shares in China will enable the company to tap into the Chinese capital market and raise capital for the expansion of its operations. The net proceeds from the offer is estimated at 240-375 mln yuan. Of the total, about 45.48 mln yuan will be used to finance the building of extraction processes in the production of drop pills at its Tianjin No.6 traditional Chinese medicine factory. Another 101.1 mln yuan will be used to finance a joint-venture investment involved in the production of anti-bacterial medication. About 40.68 mln yuan will be used to finance Tianjin Lerentang pharmaceutical factory's second phase expansion. It said about 44.850 mln yuan will be used for building production and ancillary facilities at the Tianjin No.6 traditional chinese medicine factory. Another 60.7 mln yan will be used to finance a joint-venture investment in the extraction of natural medical substances and purification processes. The remaining amount will be used for working capital, the company added. |
| (Post 8 of 6500) 02/19/2000.12:00:00 |
| Author : |
Real good news for TJZX share holders. This means its "A" shares offer price is between US$0.68 to US$1.05. This company is doing very well in China. |
| (Post 9 of 6500) 02/22/2000.14:28:00 |
| Author : |
It almost retest previous high of US$0.51 way back early-Jan 2000. Successful close above US$0.485 (upper side of the gap previously mentioned) with on-going supporting volume looks very positive. In fact, it has brk above short-term downtrend line drawn way back Nov '99 and even brk free above congestion consolidation between US$0.415 ~ US$0.44 Rdgs |
| (Post 10 of 6500) 03/22/2000.12:43:00 |
| Author : |
For archival: Singapore-listed Tianjin Zhongxin Plans China Shr Sale SHANGHAI (Dow Jones)--Singapore-listed Tianjin Zhongxin Pharmaceutical Co., a Chinese pharmaceutical company, said Friday it plans to offer 45.8 million Class A shares for Chinese investors. The shares will be priced at between 5.50 yuan ($1=CNY8.28) and CNY8.50 each, raising raise between CNY240 million and CNY375 million in net proceeds, the company said in a statement. The domestic share offering comprises 12.2% of Tianjin Zhongxin's enlarged issued share capital. Tianjin Zhongxin, which is based in northern China, is seeking approval from China's securities regulators and its shareholders for the listing, the company said. The announcement did not say which of China's two stock exchanges the Class A shares will be listed on. Upon completion of the listing, and after adjusting for net proceeds from the listing, Tianjin Zhongxin's net tangible assets per share would be between CNY3.11 and CNY3.47, versus CNY3.03 currently, the company said. EPS AT CNY0.35 Post-Listing After listing, Tianjin Zhongxin's earnings per share will be CNY0.35, based on its audited financial year 1999 results and a post-flotation capital of 375.45 million shares. This compares with earnings per share of CNY0.40, based on financial year 1998 results, and a pre-listing capital of 329.65 million shares, it said. Tianjin Zhongxin will use net proceeds from the domestic share listing for the following purposes: CNY45.48 million to finance construction of new facilities at Tianjin No. 6 Traditional Chinese Medicine Factory. Another $12.18 million, or CNY101.10 million, to finance a proposed joint-venture company producing anti-bacterial medication; About CNY40.68 million to finance the phase two expansion of Tianjin Lerentang Pharmaceutical Factory; About CNY44.85 million to construct production and ancillary facilities at Tianjin No. 6 Traditional Chinese Medicine Factory. Around $7.31 million, or CNY60.7 million, to finance investment in a joint-venture company engaged in extracting natural medicinal substances and in purification processes. The balance will be used for working capital. |
| (Post 11 of 6500) 03/28/2000.12:57:00 |
| Author : |
Tianjin FY Net CNY128.6M Vs CNY131.1M Tianjin Zhong Xin Pharmaceutical Co. Figures are in yuan. 1999 Net Profit CNY128,610,000 vs CNY131,081,000 Pretax Profit 63,436,000 vs 73,093,000 Revenue 412,366,000 vs 286,069,000 Per Share Net Profit 0.39 vs 0.49 Dividend 0.22 vs 0.22 |
| (Post 12 of 6500) 03/28/2000.14:05:00 |
| Author : |
Tianjin Zhong Xin 1999 net profit 128.610 mln yuan vs 131.081: IAS Tianjin Zhong Xin Pharmaceutical Group Corp Ltd 1999 results: Net profit - 128.610 mln yuan vs 131.081 mln Sales - 412.386 mln yuan vs 286.069 mln Pre-tax profit - 163.466 mln yuan vs 167.441 mln EPS - 0.39 yuan vs 0.40 Final div - 0.22 yuan; unchanged The results were compiled according to international accounting standards. The company said it is planning to launch an initial public offering of new shares in China to raise funds for its new pharmacuetical projects and expansion of existing facilities. |
| (Post 13 of 6500) 05/18/2000.19:57:00 |
| Author : |
Can this stock move with China inclusion to WTO soon. Seems to hold at US$0.40. |
| (Post 14 of 6500) 05/18/2000.23:49:00 |
| Author : |
Hi, Holding some on hand, how does the listing in china affecting the share pricing? |
| (Post 15 of 6500) 06/08/2000.10:57:00 |
| Author : |
Keep an eye on this stock....accumlation has been taking place over past six months. Why do I say this? Take a look at the charts, and you will see alot of little ripples, sort of multiple 'W' patterns. Further, a total of 34.8mil shares have changed hands since Dec 1999, out of a total of 100 million issued shares. That quantity was done between US35.5c and 51c (giving a simple average of 43.25c) and followed a big plunge down from the June 1999 all-time high of US83.5c! Appreciate if someone would search for broker reports and comments and share with all here at SI? Haven't quite studied the profile of the company yet, and therefore unable to say much else from FA perspective. The stock is currently trading on PEs of 10x. There is also a story (see archives) of a planned listing of 'A' local shares on the chinese exchanges, that could bring attention to this long ignored stock. No vested interest yet. Just my 2.5c worth |
| (Post 16 of 6500) 06/08/2000.11:11:00 |
| Author : |
TianJin looks good on the chart and P&L, however interest is still focus on Tech stocks at the moment. Suggest a buy and hold for 3-6 mths down to road to realise greater returns. |
| (Post 17 of 6500) 06/08/2000.12:18:00 |
| Author : |
dividend of .22 yuan= 0.044 singapore cents,tax exempt ex on 3/7 dividend yeild of 6.6% |
| (Post 18 of 6500) 06/08/2000.12:35:00 |
| Author : |
warren tianjin is on my buylist & it is in my website with price chart http:myhome.asia1.com/home/s/stockmarketgeometry the TA shows turning point at 35.5cts & at current prices risk/reward ratio is good |
| (Post 19 of 6500) 06/08/2000.13:14:00 |
| Author : |
Me too eyeing this stock, agree to previous posting and had done some readup on the company. Comapany had being making handsome profits for the past 5 years and strong market with its products in China and Asia. High assets with low liabilities. lastly as mentioned, good Dividends every year also. Conclusion? Good counter! vested interest as well |
| (Post 20 of 6500) 06/08/2000.14:43:00 |
| Author : |
Hi Warren, I too have been buying this stock from below 40¢....Coy is involved in the manufacture of both Chinese & Western pharmaceuticals....and has been able to maintain satisfactory earnings, but has been neglected by many investors coz of its China link....which could possibly look good in the near future when rotational play switches to China-linked stocks.....so, I buy early. **vested interest since last week** |
| (Post 21 of 6500) 06/08/2000.14:57:00 |
| Author : |
Carol, Jus, Rem, loglog, Thanks for the comments, they are appreciated. I still need to appreciate where the strength and pressure points for these companies are. China's entry into WTO could either spell plenty of opportunities (if they do OEM drug manufacturing and distribution) or disaster (cos market admits new competitors. So appreciate if anyone has broker research, however old, to share? Wci, Your HTML link shows up blank. Is there an error? |
| (Post 22 of 6500) 06/08/2000.17:32:00 |
| Author : |
warren the link is http://myhome.asia1.com/home/s/stockmarketgeometry btw, philips securities has a very old research report & wil try to locate it for you asap |
| (Post 23 of 6500) 06/08/2000.23:16:00 |
| Author : |
Wci, Thanks for the link. Yes I saw your rather complex chart, and while I don't understand the message you are portraying, I figure you agree that the outlook is bullish. Great. Would you however, update with a few more comments as your charts were dated 21 April 2000? |
| (Post 24 of 6500) 06/09/2000.23:00:00 |
| Author : |
warren decided to do a simpler chart & the TA shows: -the price moves in 35.5cts ranges significantly -the 7 day Moving Average fit the prices well & prices are now above the MA7 -My geometry studies (u seen them) show turning point at 35.5cts which coincidentally is same as the price range! -the trend is Up but TJ is a laggard & abit slow  |
| (Post 25 of 6500) 06/10/2000.02:33:00 |
| Author : |
No idea why most of u are bullish on this counter. Maybe because fundamental wise. But based on TA. I beg to differ. TA is more for short term. So I zoomed in on the more recent data for charting purposes. An upside breakout at pt does show a bullish sign however volume traded then was weak and not really a good confirmation for this breakout. Anyway if u had bought this counter when price crossed the 10day moving average at abt .38-.385 or the price breakout at .395-.40, it should be considered rather safe. However for now, price has made a new resistance. With the ROC/Momentum indicator showing a downtrend. RSI seems to have tested its resistance, failing to break and therefore turning down. I do see support of this counter at 0.39. However to assume that its bullish now based on TA would not be correct.  No vested interest. Just concern. =) |
| (Post 26 of 6500) 06/13/2000.01:18:00 |
| Author : |
INTERESTED PERSON TRANSACTION Introduction The Board of Directors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company" or " TZXP") is pleased to announce that the Company has on 12 June 2000 entered into an acquisition agreement ("Acquisition Agreement") with its holding company, Tianjin Pharmaceutical Holdings ("TPH")") whereby the Company shall acquire a group of companies and entities owned by TPH known as the Da Ren Tang Group (details of which are set out hereafter) from TPH on the terms and conditions of the Acquisition Agreement ("Proposed Acquisition"). Consideration Under the Acquisition Agreement, it is agreed that TZXP shall acquire the Da Ren Tang Group from TPH for a nominal cash consideration of Rmb1.00, subject to certain conditions being fulfilled. However, under the terms of the Acquisition Agreement, TZXP has to absorb all assets and liabilities of the Da Ren Tang Group, which was audited by the auditors of the Company, Pricewaterhouse Coopers ("Auditors") with reference to the financial position as at 30 June 1999, the reference date of the Proposed Acquisition ("Reference Date"). The effective date of transfer of ownership ("Transfer Date")is contractually agreed to be on 30 June 2000. The terms of the Proposed Acquisition had been fixed on a zero net asset value basis, which means that an adjustment of payment will be made based on a post-acquisition audit to be performed by the Auditors, in order to ascertain the asset net value of Da Ren Tang as of the Transfer Date. Background to the Da Ren Tang Group and the Proposed Acquisition At the time of the listing of the Group on the Main Board of the SGX-ST in June 1997, the Directors of the Company identified one of the key strategies for future growth of the Group to be the expansion of its manufacturing capacities, including widening of its product range, as well as the development of its distribution network. These plans were stated in the section headed "Future Plans and Prospects- Market Development" in the listing prospectus of the Company dated 11 June 1997 (the "Prospectus"). The Company also stated in the Prospectus that it would take steps to achieve these two strategic objectives. In line with the above strategies, the Directors of TZXP are proposing to carry out the Proposed Acquisition of the Da Ren Tang Group from TPH . The Da Ren Tang Group comprises of the following entities: 1. Tianjin Da Ren Tang Pharmaceutical Factory ("Da Ren Tang")") 2. Tianjin Traditional Chinese Medicine Group Hangu Company ("Hangu")) 3. Tianjin Traditional Chinese Medicine Group Hebei Company ("Hebei")") 4. Tianjin Traditional Chinese Medicine Group Hedong Company ("Hedong")") 5. Tianjin Traditional Chinese Medicine Group Heping Company ("Heping")") 6. Tianjin Traditional Chinese Medicine Group Hexi Company ("Hexi")") 7. Tianjin Traditional Chinese Medicine Group Hongqiao Company ("Hongqiao")") 8. Tianjin Economic and Technology Development Zone Long Shun Rong Company ("Longshunrong Supreme") 9. Tianjin Traditional Chinese Medicine Group Nankai Company ("Nankai")") 10. Tianjin Traditional Chinese Medicine Group Tanggu Company ("Tanggu")") 11. Tianjin Xin Xin Pharmaceutical Corporation ("Xinxin") 12. Tianjin Medicine Group Company Xinxing Breeding Factory ("XinXing Breeding Plant")") 13. No. 1 and No. 2 Branches of Tianjin Medicine Group Company ("No. 1 and No. 2 Branches")") 14. Chengyao Branch of Tianjin Medicine Group Company ("Chengyao Branch")") 15. Yaocai Branch of Tianjin Medical Group Company ("Yaocai Branch")") 16. Chuyun Branch of Tianjin Medical Group Company("Chuyun Branch")") The Da Ren Tang Group is principally engaged in the following businesses:- Name of entity/ department Principal Activities Da Ren Tang Controlling company of the Da Ren Tang Group, which is also engaged in the manufacture of traditional Chinese medicine, with over 189 product types. Xinxin Manufacture and distribution of raw materials for Western medicine (over 10 types) and Western medicine (over 40 types). 8 district subsidiaries(1) Own and operate a total of 202 retail outlets in Tianjin City, as demarcated by the respective districts of Tianjin City. Longshunrong Supreme Distribution and retail of high-end medical and healthcare products Currently has one retail outlet. Xinxing Breeding Plant Breeding and farming of deer, for the antler of deer which is a precious medical raw material. No. 1 & No. 2 Branches Retail and wholesale of in-house products and certain products of related companies within TPH Group including TZXP to medical/healthcare companies within Tianjin City. Chengyao Branch Retail of in-house products as well as certain products of related companies within TPH including TZXP through operation of 98 sales offices outside Tianjin City in other parts of the PRC. Yaocai Branch Procurement center for Da Ren Tang Group as well as other related companies within TPH including TZXP. Chuyun Branch Provision of warehousing and logistics operations for Da Ren Tang Group as well as to other related companies within TPH including TZXP. Note(1) Companies No. 2 to 7 as well as 9 and 10 above. Rationale The Proposed Acquisition meets the Group's plans for future business expansion. The Group considers the Proposed Acquisition to be attractive for the following reasons: (a) The bulk of the TZXP Group's Chinese pharmaceutical products were previously sold through Da Ren Tang Group's No. 1 & No. 2 Branches and Chengyao Branch, as well as the retail outlets. This accounted for approximately 60% and 43% of the TZXP Group's annual sales for FY1998 and FY1999 respectively. With the acquisition of Da Ren Tang Group, the TZXP Group immediately acquires an established and widespread sales and distribution network for its products and no longer needs to sub-contract the function to these 2 branches. In addition, the distribution network is formed as a result of over 40 years of operations and has wide customer base and market presence. (b) As the procurement operations of the combined TZXP Group will be centralized and controlled by TZXP in co-ordination with Yaocai branch, the combined TZXP Group would be able to enjoy savings from bulk purchases of raw materials from its suppliers. The same benefit of economies of scale would apply to the warehousing and logistic function, which is centrally handled by the Chuyun Branch. The sales, administrative and marketing functions of TZXP Group and Da Ren Tang Group will also be controlled and managed by TZXP. The combined TZXP Group would be able to enjoy cost savings from a reduction in any duplication of sales and marketing efforts as well as in administrative costs. In addition, the extensive distribution network would provide a platform for TZXP in restructuring it into chain store operations to maximize the sales effort. (c) TZXP could acquire Xinxin, which is engaged in manufacturing of raw materials for western medicines (over 10 types) and western medical products (over 40 types). This will strengthen the western medicine product mix of TZXP. In addition, the Da Ren Tang Group has over 189 types of Chinese medicine products. This will also further enhance the wide product range of TZXP Group, particularly with regard to Chinese medicine products with other therapeutic properties. (d) Xinxin makes direct sales for its raw materials to export markets like Europe and US and such sales constitute 80 % of its own sales for FY 1999. The Proposed Acquisition allows the combined TZXP Group to diversify its revenue source as its export sales could be boosted. (e) To date, there are an estimated 44 products which are manufactured and sold by Da Ren Tang Group with similar therapeutic properties as the products sold by TZXP Group. Although the products are in traditional dosage form, its Huoxiang Zhengqi (which is similar to TZXP's Huoxiang Zhengqishui) is in capsule form, as products of TZXP. In addition, Da Ren Tang Group controls a major research center, which is accorded with "state" status. The research center undertakes research and development effort independently of TZXP. This would give rise to potential conflict of interest on product development. Upon the acquisition of the Da Ren Tang Group, such conflicts of interest would be eliminated as such products would now be manufactured and sold by the combined TZXP Group post acquisition and the research center would be absorbed by TZXP. (f) In addition, TZXP's purchases have previously been made from Yaocai Branch while its sales have previously been made through Chengyao Branch and No. 1 & No. 2 Branches. The related party transactions relating to the sales and procurement would be eliminated upon the acquisition of the companies and entities within the Da Ren Tang Group. (g) Da Ren Tang is a widely recognized name within the Tianjin Municipality and its adjacent provinces and even the larger market of China due to its long operations history since 1914. It presently has over 189 products in its stable. Its flagship products are particularly well received in the consumer market within China. The widely recognized brand name provides a platform for the Company to intensify sales effort of the products after the Proposed Acquisition. In addition, the Company will not need to set aside substantial financial resources and marketing effort to build up brand awareness for the wide range of products. Conditions Precedent of the Acquisition Agreement The duty of the parties to perform their respective obligations under the Acquisition Agreement on the Transfer Date and on the completion date of the Proposed Acquisition ("Completion Date"), is subject to, inter alia, the following conditions: (a) all relevant approvals, consents, permits, confirmations and/or waivers from TPH, Tianjin City State-owned Assets Bureau and/or all other relevant authorities or third parties having been obtained; (b) all necessary legal procedures, registrations for the Proposed Acquisition having been completed by Da Ren Tang; (c) all necessary approvals of the respective directors/shareholders/labor organizations of the parties and Da Ren Tang having been obtained; (d) the approval of the Singapore Exchange Securities Trading Limited having been obtained for the Proposed Acquisition; and (e) the representations and warranties made by TPH under the Acquisition Agreement remaining true, accurate and effective at the Transfer Date and Completion Date. Financial Effects The financial effects of the Proposed Acquisition on the TZXP Group are set out below:- As at
In summary, assuming the Proposed Acquisition was affected on 1 January 1999, the Proposed Acquisition would have the following affects:- (a) a decrease on the Group'sNTA per share; (b) a decrease on the Group'sEPS; and (c) an increase on the Group'sgearing ratio. The decrease on the Group's NTA per share and EPS is largely due to downward adjustments in consolidating the financials of both TZXP Group and Da Ren Tang Group. More details on this adjustments are set out at the Circular. Shareholders' Approval As TPH is the ultimate owner of the entities within the Da Ren Tang Group and a substantial shareholder of TZXP, the Proposed Acquisition represents as interested person transaction under Chapter 9A of the Listing Manual of the SGX-ST. Notwithstanding the nominal cash consideration of Rmb 1.00 to be paid by TXZP, the approval of the Shareholders will be sought for the Proposed Acquisition in view of the quantum of the assets and liabilities to be absorbed. A circular setting out the details of the Proposed Acquisition and the notice of extraordinary general meeting ("EGM") will be despatched to the Shareholders in due course. Substantial Shareholders' and Directors' Interests TPH is the ultimate owner of Da Ren Tang and a substantial shareholder of the Company holding approximately 59.05% of the issued and paid-up capital of the Company. In view of TPH's interest in the Proposed Acquisition, TPH and its associates will therefore abstain from voting at the EGM in respect of its shareholding in TPH. Save as disclosed above, none of the substantial Shareholders and Directors has any interest, direct or indirect, in the Proposed Acquisition. Statement by Audit Committee Having reviewed the terms of and rationale for the Proposed Acquisition, the Audit Committee of the Company is of the opinion that the terms of the Proposed Acquisition are on normal commercial terms and are not prejudicial to the interests of the Shareholders. Directors' Responsibility Statement The Directors of the Company (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and the opinions expressed herein are fair and accurate and that no material facts have been omitted and they jointly and severally accept responsibility for this announcement. By Order of the Board Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Submitted by Shen Ming Qi, Financial Secretary to the Board on 12/06/2000 to the SGX |
| (Post 27 of 6500) 07/16/2000.14:43:00 |
| Author : |
Good dividend yield. US $0.0265/share. Worth a buy for dividend |
| (Post 28 of 6500) 07/17/2000.02:42:00 |
| Author : |
Hi The dividend yield for this stock is good. But i don't like the decreasing margin. Better to wait and see |
| (Post 29 of 6500) 08/01/2000.03:45:00 |
| Author : |
PROPOSED ACQUISITION OF TIANJIN DA REN TANG GROUP FROM TIANJIN PHARMACEUTICA HOLDINGS 1. Further to the announcement on 12 June 2000 by the Board of Directors of the Company in connection with the Acquisition, the Board of Directors is pleased to announce that the shareholders of the Company have via an Extraordinary General Meeting held on 31 July 2000 approved and authorized the following: (a) the Acquisition by the Company from Tianjin Pharmaceutical Holdings(TPH) of Da Ren Tang Group for a nominal cash consideration of RMB1.00 on the terms and conditions of the acquisition agreement dated 12 June 2000 entered into between the Company and TPH; (b) the Directors to take all necessary steps to give effect to and complete the Acquisition and to make such amendments (not being of a material nature ) to any of the terms of the Acquisition agreement as they think necessary or desirable; and (c) the Company to enter into the various recurrent interested persons transactions more particularly described in the Circular to shareholders dated 15 June 2000 (the "Circular"), such approval to be valid for one year from 31 July 2000 or until the conclusion of the next Annual General Meeting of the Company. 2. Under the Acquisition agreement, it was agreed that the Company shall acquire Da Ren Tang Group from TPH at nominal consideration of RMB 1.00 subject to certain conditions being fulfilled, inter alia: (a) all relevant approvals, consents, permits, confirmations and/or waives from TPH, Tianjin City State-owned Assets Bureau and /or all other relevant authorities or third parties being obtained; (b) all necessary approvals of the respective directors/shareholders/labor organizations of the parties and Da Ren Tang being obtained; (c) the approval of the Singapore Exchange Securities Trading Limited being obtained for the Acquisition. 3. The Company is to absorb all assets and liabilities of the Da Ren Tang Group which has been audited with reference to the financial position as at 30 June 1999. The effective date of transfer of ownership is contractually agreed to be 30 June 2000. 4. The terms of the Proposed Acquisition have been fixed on a zero net asset value basis. As such, a post-acquisition audit will be performed by the Company's auditors to ascertain the net asset value of Da Ren Tang Group as of 30 June 2000, and an adjustment of payment will be made based on the net asset value position. Such audit will be done in conjunction with the Company's annual audit for FY2000. Details relating to payment and adjustment are more particularly described in the Circular. 5. The rational for and the anticipated benefits to the Company for the Acquisition are as follows: (a) The Company will acquire an established and widespread sales and distribution network for its products. (b) The Company will reap benefits from a centralized control of key operations functions in procurement, warehousing and logistics, sales and marketing, and backroom functions. (c) The Company will be able to diversify its product range and increase its sale of western medicine. (d) The Company will be able to diversify its revenue source through increased export sales by further diversification of markets. (e) Conflicts of interest on product development between the Company and Da Ren Tang Group will be eliminated. (f) Previous substantial related party transactions between the Company and Da Ren Tang Group will be eliminated. (g) The Company will not need to set aside substantial financial and marketing effort to build up brand awareness for the wider range of products as Da Ren Tang's flagship products are well received in China'sconsumer market. (h) The Company will be able to centralize the two parties' research and development programs. In summary, the Acquisition would be synergistic and complementary to the Company's existing operations and add-value to the growth of the Company. 6. Having reviewed the terms and conditions of the Acquisition, the Audit Committee of the Company is of the opinion that the Acquisition is on normal commercial terms and are not prejudicial to the interests of the Company's shareholders. Submitted by Shen Ming Qi, Financial Secretary to the BOD on 31/07/2000 to the SGX |
| (Post 30 of 6500) 08/04/2000.20:23:00 |
| Author : |
Tian Jin Zhong Xing: ride the China Market rise. I have been noticing the continueous rise of China stock markets which started early this year. I do not see any fundamental problems with Chinese economy: Stable leadership, improved economy conditions, potential joining WTO. Compared to other China-listed stocks, TJZX is undervalued. Compared to many Singapore-listed stocks, TJZX has been performing relatively OK, meaning it is a kind of "bear-resistant" stock. I bought 2 lots at 0.37 today. |
| (Post 31 of 6500) 08/09/2000.10:49:00 |
| Author : |
Profits for the past 4 years: 1996 1997 1998 1999 146.3 137.5 131.2 130 (RMB m, after tax) NA 49 40 39 (RMB, cents/share) The trend is declining, but it has stabalized in 1999, and the sales had actually increased by 44%. With China economy turning around now, we are not to be blamed for assuming this company will start to make more profit. I notice that it ALREADY spent a lot of money on advertizing, that should reap some returns. In 1998, the Group received technical and marketing fees amounting to Rmb25million from its associated company, Tianjin Smithkline & French Laboratories Limited (TSKF). No such fee was received in 1999 and this is conpensated to some extent by the increase in the Group's share of profit in the associated company. If this fee were excluded from 1998 operateing profit, the Group's 1999 operating profit would show an increase of 31%. Therefore, we could bravely assume a price/earings ratio of about 10, that translates into a share price of 39*10=390 (RMB cents)=390/8.3=47 US cents. So the current price of US 36C is a discount of about 24% to my estimation. It should be noticed that this company has made profits for all the past 4 years (listed years) and paid always 22 RMB cents (US 2.7Cents) as dividend for the past 3 years (NA to 1996), so there are reasons to believe it is not a risky company. The chart, on the other hand, does not look good, but I doubt there is much for the price to fall further. It is hard to find a company whose fundamentals and technicals are both good. An example is GP Batteries. |
| (Post 32 of 6500) 08/21/2000.12:05:00 |
| Author : |
Approved: A-share listing in China. I accidently run into the China-Economy section of Lian He Zhao Bao, and it says that Tian Jin Zhong Xing had received approval for listing in China's A-share market. (I do not remembe the details, but I read it last Saturdy's on-line LianHeZhaoBao version) |
| (Post 33 of 6500) 08/22/2000.01:45:00 |
| Author : |
²»Äܲ»ÁôÒâµÄÖйúÃÍ¹É TJZX will second list 40 million shares in shanghai stock exchange. The average P/E of chinese A shares is about 50X. so this counter will shine in the near future. believe it or not, one of my chinese friend,a experienced stock broker said, the fair value should be at least 40X P/E, about 2 USdollors. but,all chinese stocks is papertiger, the real thing beneath the beautiful result is corruption and cronism. so be careful of any chinese stock,otherwise ur whole body will be scorched to ash, not only ur finger. i do not understand why there is not some businessmen from china to singapore with a briefcase full of us dollors cash to buy this counter for future's arbitration. i believe it will be second listed in one or two month,that time is my reaping season. who can acquire some tidings about when will this counter be listed, and share the tidings with every one. the IPO price of TJZX is 0.68 us dollor. highest price is about 1.70 lowest is 0.13 i like the corruption rotted smell of tjzx. all chinese have used the medicine named ¿µÌ©¿Ë(±ÇÈû¡¢Í·Í´¡¢´òÅçÌ磬24Сʱ»ºÊͽºÄÒ£©£¬sino-american joint venture between TJZX and Smith-Klain. short term target:US$0.80 long term targer: US$2.00 best time to sell:US$0.79. cheers.!  |
| (Post 34 of 6500) 08/23/2000.22:34:00 |
| Author : |
Tianjin Zhong Xin Pharmaceutical Group has announced that it intends to list 45.8m new shares in China. This will represent 12.2% of the enlarged share capital of the company. The shares will be "A" shares. - by HR (Section: Archives) |
| (Post 35 of 6500) 08/23/2000.22:48:00 |
| Author : |
°¢ÃÖÍӷ𣡠sniff away temporary negtive market change,i will insist my standpoint on this counter. at least it has enough cash to give me fat dividend. the most beautiful drug stock more than 100 million rmb net profit every year. no respond.pityful! |
| (Post 36 of 6500) 08/29/2000.18:14:00 |
| Author : |
Will go up when issue A shares due to price differences.... gotta announce result and might just announce this good news.... |
| (Post 37 of 6500) 08/30/2000.10:27:00 |
| Author : |
Accumulate....going to announce good news! Last chance.. |
| (Post 38 of 6500) 08/31/2000.03:05:00 |
| Author : |
Tianjin Zhong Xin 1H Net CNY82.7M Vs CNY74.8M
(US$1=CNY8.2675) |
| (Post 39 of 6500) 08/31/2000.03:33:00 |
| Author : |
ACQUISITION OF DARENTANG GROUP Further to the previous announcement by the Company on 31 July 2000 in respect of the acquisition by the Company of the Darentang Group from Tianjin Pharmaceutical Holdings under the acquisition agreement of 12 June 2000 (the"Acquisition Agreement"), the Directors of the Company wish to announce that the parties have agreed to amend the effective date of transfer of ownership under the Acquisition Agreement from 30 June 2000 to 30 September 2000 in order to allow the timely satisfaction by the parties of all necessary conditions precedent under the Acquisition Agreement. By order of the Board Submitted by Shen Ming Qi, Financial Secretary to the Board of Directors on 30/08/2000 to the SGX |
| (Post 40 of 6500) 09/01/2000.10:03:00 |
| Author : |
Targeted price: US$94 cents. Why: The first half year profit is 25 cents RMB, an increase of 8% compared to the same period a year ago. Assume this momentum contines, the next half year may see a profit rise of 4%, that means 25*1.04=26 RMB cents. Thus the annual profits per share for 2000 will be 51 cents RMB(=51/8.3 = 6.1 cent US$), an increase of 30% over 1999 (51/39 = 1.3). TJZX should be doing better next year according to my feeling, so I should maintain the same PER of 15 (see my previous post on Aug. 4), that translates into the targeted price of 15 x 6.1 = 91 cents US$ at the end of 2000. |
| (Post 41 of 6500) 09/01/2000.10:15:00 |
| Author : |
Good shares are just not underpinned by the need to be profitable, but the company has to be a PR maverick as well. The less a company interacts with the investing communities, e.g. E&E, Magnecomp and a lot of others will only see people eschew from these stocks. Tianjin while it is a profitable company, will continue to see little interest from the Singaporean investors here. |
| (Post 42 of 6500) 10/18/2000.00:54:23 |
| Author : |
Tianjin Zhong is emerging as big player in China's pharm. industry. Not only is it a defensive stock in this volatile downword markets due to its indutrial characteristics, it also has a very good growth prospect. It is a bluechip in China, a WTO in its favor counter, an influencial maker of natural Chinese medicine that is more and more popular and recognised worldwide, a biotech manufacturer (one of its major products "Anflon" is a biotech product), a dual listing concept with its A share to be listed in China Exchange within this month ..... With its current price ( US$0.34/share) and daily trading volumes, it is overwhelmingly undervalued and ignored by the local market. If the situation still goes on like this, it can consider delisting from SGX where most traders pay too much attention to the shares of those contract manufacturers with decreasing profit margins and diminishing competative advantages. Do you agree on what I said?
SI |
| (Post 43 of 6500) 10/18/2000.01:26:38 |
| Author : |
Don't buy anything now!!! |
| (Post 44 of 6500) 10/18/2000.08:04:28 |
| Author : |
To Fzhang
agree to what u say, if got maney to keep it for more than a yr. it should grow moreover the yield is good but the exchange rate is higher now.highest 1.72 few months after IPO in 1997 and about 90c in 1999. The only trouble it is far away in China for analysis to analyse here |
| (Post 45 of 6500) 11/09/2000.13:57:59 |
| Author : |
Hi Erlee, I found some analysis on Tianjin that you might be interested in reading. I too find it hard to get good analysis but it's out there if you have time to look for it.
http://www.stockhouse.com.sg/shfn/nov00/110900_tian.asp |
| (Post 46 of 6500) 12/05/2000.22:57:57 |
| Author : |
Re-organization of Subsidiaries into Branches
Further to the resolutions passed by members of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (hereinafter known as the "Company") on 31 July 2000 in connection with the Company's acquisition of and merger with Tianjin Darentang Group, the Board of directors hereby wish to announce that in connection with its continual development and growth : - 1. The Company shall re-organize its following subsidiaries, namely, Tianjin Darentang Pharmaceutical Factory, Tianjin Xinxin Pharmaceutical Company, Tianjin Economic Technology Development Zone Long Shun Rong Company, Tianjin Chinese Medical Group Hongqiao Company, Tianjin Chinese Medical Group Nankai Company, Tianjin Chinese Medical Group Heping Company, Tianjin Chinese Medical Group Hebei Company, Tianjin Chinese Medical Group Hedong Company, Tianjin Chinese Medical Group Hexi Company, Tianjin Chinese Medical Group Tanggu Company, Tianjin Chinese Medical Group Hangu Company, Tianjin City Beichen District Xinxing Breeding Farm, and Tianjin City Xinxin Chemical Pharmaceutical Company (collectively, the "Transformed Enterprises"), into branches known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Darentang Pharmaceutical Factory, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Xinxin Pharmaceutical Factory, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Long Shun Rong Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hongqiao Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hong Nankai Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Heping Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hebei Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hedong Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hexi Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Tanggu Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Hangu Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Xinxing Breeding Farm, and Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Xinxin Chemical Branch respectively. All assets and liabilities of the Transformed Enterprises shall be owned and borne by the Company. 2. The original branches of the Tianjin Darentang Pharmaceutical Factory, namely, the Medicine Branch, the Medical Supplies Branch, and the Storage and Transportation Branch, shall be re-organised into Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Medicine Branch, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Medical Supplies Branch, and Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Storage and Transportation Branch respectively. 3. The original No. 1 and No. 2 Branch shall be re-organized into Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Medicinal Branch and Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Medical Products Distribution Center respectively. Submitted by MoHao, Secretary of the BOD on 05/12/2000 |
| (Post 47 of 6500) 12/18/2000.09:22:18 |
| Author : |
Announcement in relation to the Completion of Acquisition of
Tianjin Darentang Pharmaceutical Factory The board of directors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") hereby announce that the Company has completed the acquisition of Tianjin Darentang Pharmaceutical Factory ("Darentang") pursuant to the "Acquisition Agreement of Tianjin Darentang Pharmaceutical Factory" entered into between the Company and Tianjin Pharmaceutical Holdings on 12 June 2000. The Company's auditors, PriceWaterhouseCoopers, had completed the audit on Darentang on the Transfer Date of the acquisition (ie. 30 Sep 2000) and the audit report has been accordingly issued. Submitted by Shen Mingqi, Financial Secretary of the Board on 16/12/2000 |
| (Post 48 of 6500) 04/02/2001.00:28:17 |
| Author : |
Below is pulled from Source : Dow Jones 01/04/2001.
With dividend at CNY 0.27 per share, 1 lot of Tianjin yields dividend of US$32.61. With 1 lot at US$305, this give a 10.69% dividend yield. Heh, have I got it wrong! Is it the SGX that is a problem and or its participants who are always punting the hot stocks, chasing false hopes and rumours. Why the neglect for such value stocks! Have vested interests; therefore treat comments with a pinch of salt. The sad truth is that the share price may just drift lower XD. Such is the trend of the past. Tianjin Zhong Xin Pharma Group. - Singapore Year to Dec. 31: 2000 1999 Revenue CNY822,646,000 CNY412,366,000 Pretax Profit 55,015,000 63,436,000 Net Profit 92,673,000 128,610,000 Per Share Net rofit 0.28P 0.39 Dividend CNY0.27 CNY0.22 Earnings per share is on a fully diluted basis. (US$1=CNY8.2775) |
| (Post 49 of 6500) 04/30/2001.12:55:06 |
| Author : |
Any news on the sudden surge? |
| (Post 50 of 6500) 04/30/2001.14:26:32 |
| Author : |
Heard rumour tt they are doing a dual listing in Shanghai at
10RMB Don't know how true. If it is, will it be another East Asia Tech?  |
| Pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 of 130 |
|
Copyright © 2005 ShareInvestor Pte Ltd. All Rights Reserved. Please read our General Disclaimer & Warning carefully. Use of this Website constitutes acceptance of the Terms of Website Use. For Members, please read our Membership Terms and Conditions carefully. |
Design by InfiniteSparks
|